Puma touts neratinib's promise in breast cancer; Novartis cancer drug flunks Phase III;

@FierceBiotech: EuroBiotech: Shire steps up arGEN-X alliance, Big Pharma gives MRC drugs, Woodford backs Midatech IPO. More | Follow @FierceBiotech

@DamianFierce: $BMRN's buyout subs are called Falcons and Giants, which could be an NFL thing or a ref to some obscure fantasy novel. More  | Follow @DamianFierce

> Puma Biotechnology's ($PBYI) in-development neratinib notched a 30% response rate in Phase II breast cancer trial with diarrhea, a nagging side effect for the drug, showing up as a dose-limiting toxicity. More

> Novartis' ($NVS) plan to expand the indication for the cancer drug Afinitor came up short as the drug failed to significantly beat out placebo in a Phase III trial on HER2-positive breast cancer. Story

> Alnylam ($ALNY) is talking up its pipeline of RNAi therapeutics, part of its "5x15" strategy through which it plans to expand the applications for its proprietary technology. Release

Medical Device News

@FierceMedDev: DARPA's ElectRx seeks innovators to transform neuromodulation devices. More | Follow @FierceMedDev

@EmilyWFierce: #India's NPPA extends pricing policy on drugs, adding fuel to price cap fire. Story  | Follow @EmilyWFierce

> Judge advises Bard to settle vaginal mesh implant cases. Article

> Strong one-year data for Boston Scientific chronic pain implant, but reimbursement change stymies sales. More

> FDA works to improve medical device approval times. News

Pharma News

@FiercePharma: Kansas State researchers model U.S. outbreak of foot-and-mouth. Story  | Follow @FiercePharma

@CarlyHFierce: I think BOLERO-1 might be my favorite trial name ever. Release | Follow @CarlyHFierce

> India's NPPA extends pricing policy on drugs, adding fuel to price cap fire. News

> No pharma companies will get Danone's medical nutrition biz, because it is not for sale. More

> Novartis' bid to widen Afinitor's breast cancer reach falls short in PhIII. Story

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.